This innovative bio-electronic start-up is developing the first intelligent Evoke Spinal Cord Stimulator (SCS) System, designed to use the patient’s own neural fingerprint to monitor and adapt the dose of electrical stimulation they receive to treat pain. This method tailors the therapy to meet each individual patient’s needs in real-time and is the first therapeutic device designed to both constantly read and modulate signals on the spinal cord to treat chronic pain.
HOW THEY’RE DISRUPTING
Studies show that those who used the stimulator system experienced an average of 80% sustained improvement in their back pain after six months. The patients also had meaningful improvements in function, disability, and sleep. In designing this system, Saluda Medical has advanced and expanded the field of bio-electronic medicines.
Low back pain is the leading cause of disability worldwide, affecting an estimated 540 million people at any one time.
INVESTMENTS AND FUTURE
The company has received $49.5m in funding from two disclosed funding rounds, with investors including Action Potential Ventures, BioScience Managers Ltd and Medtronic.